Catalyst Pharmaceuticals, Inc. (CPRX)
NEUTRALファンダメンタル
72
株価
$-
時価総額
$3.85B
パート1 · 企業の価値
概要
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$597M
直近12か月（2026/3/31まで）
純利益
$221M
直近12か月（2026/3/31まで）
フリーキャッシュフロー
$172M
自己資本合計
$1.01B
負債合計
$3M
流動比率
7.10
利払い倍率
-
負債/EBITDA
0.01
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$47.09
現在株価
-
安全マージン
-
適正価値レンジ
$30.61 - $63.58
推定方法
バリュエーション指標
P/E レシオ
17.42
ROE
24.5%
P/B レシオ
3.80
P/FCF
-
粗利益率
86.0%
ROIC
20.8%
収益性レーダー
Value Creation (Economic Moat)
ROIC
20.8%
WACC
8.0%
ROIC − WACC
+12.8 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
ファンダメンタル分析基準
合格（16）
- ROIC 20.8%
- Gross Margin 86.0%
- Debt/Equity ratio
- Operating Margin 44.8%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 23.6%
- Revenue Growth 5Y 37.7%
- Earnings Surprise avg 13.8%
- PEG Ratio 0.92
- Earnings Quality (OCF/NI) 0.94
- Net Margin Trend 37.1% vs 36.9%
不合格（4）
- P/B Ratio 3.80
- DCF valuation (Unknown)
- Analyst Consensus 0% Buy
- Piotroski F-Score 1/9
データなし（7）
- EPS data insufficient
- Historical price data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- Interest Coverage
- Price below Graham Number
- Share Dilution (missing shares data)
Piotroski F-スコア
重大な財務上の懸念
利益の質
中程度：利益とキャッシュの間にギャップがある
株式希薄化
株式を買い戻している。株主に友好的
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Patrick J. McEnany | Co-Founder & Non-Executive Chairman | 78 |
| Mr. Richard John Daly M.B.A. | President, CEO & Director | 64 |
| Mr. Michael W. Kalb CPA | Executive VP, Treasurer & CFO | 54 |
| Dr. Steven R. Miller Ph.D. | Executive VP, COO & Chief Scientific Officer | 63 |
| Mr. Jeffrey Del Carmen | Executive VP & Chief Commercial Officer | 54 |
| Dr. William T. Andrews FACP, M.D. | Chief Medical Officer | 60 |
| Ms. Mary Coleman | VP & Head of Investor Relations | - |
| Mr. Brian Elsbernd J.D. | Chief Compliance Officer & Chief Legal Officer | 61 |
| Mr. Gregg Russo | Chief Human Resources Officer | 62 |
| Dr. Preethi Sundaram Ph.D. | Chief Strategy Officer | 49 |
監査リスク
8
取締役会リスク
3
報酬リスク
8
株主権利リスク
4
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
Latest News
Recent headlines for CPRX, sourced from Markets Gazette.
- 4/27/2026POSITIVEItaly’s Angelini Said to Explore Acquisition of Catalyst Pharma
Catalyst Pharmaceuticals Inc. is reportedly being explored for acquisition by Italian drugmaker Angelini Pharma. This potential deal signals significant interest in Catalyst's assets and market position, suggesting a possible premium valuation for shareholders. Angelini Pharma's exploration indicates a strategic move to expand its global reach, potentially through acquiring Catalyst's product pipeline or market access. Investors will be watching for further developments, as an acquisition could lead to a substantial uplift in Catalyst's stock price.
- 4/27/2026NEUTRALItaly’s Angelini Said to Explore Catalyst Pharma Acquisition
Angelini Pharma, an Italian drugmaker, is reportedly exploring the acquisition of US-based Catalyst Pharmaceuticals Inc. This potential deal is part of Angelini's strategy to broaden its international presence. Catalyst Pharmaceuticals, trading on the Nasdaq, specializes in treatments for rare autoimmune diseases. While the exploration is in its early stages and no deal is guaranteed, the news highlights potential consolidation within the pharmaceutical sector. Investors will monitor developments for any concrete offers and the strategic rationale behind such a move.
via Markets Gazette